AMARIN CORP PLC\UK Contract Liability (Deferred Revenue)
AMARIN CORP PLC\UK (AMRN) had Contract Liability (Deferred Revenue) of $2.34 million as of 2024-03-31, per its 10-Q filed 2024-05-01.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2025-03-12
- 2024-03-31: Contract with Customer, Liability, Current $2.34M.
- 2023-12-31: Contract with Customer, Liability, Current $2.34M.
- 2023-09-30: Contract with Customer, Liability, Current $2.02M.
- 2023-06-30: Contract with Customer, Liability, Current $2.02M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2024-03-31 | $2.34M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $2.34M 10-K · filed 2025-03-12 |
| 2023-09-30 | $2.02M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $2.02M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $2.20M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $2.20M 10-K · filed 2024-02-29 |
| 2022-09-30 | $2.20M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $2.20M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $2.20M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $2.65M 10-K · filed 2023-03-01 |
| 2021-09-30 | $2.65M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $2.64M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $2.77M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $2.93M 10-K · filed 2022-03-01 |
| 2020-09-30 | $5.71M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $5.71M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $4.29M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $2.34M 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.96M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $1.96M 10-Q · filed 2019-07-31 |
| 2019-03-31 | $1.90M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $1.22M 10-K · filed 2020-02-25 |
| 2018-09-30 | $1.22M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $1.06M 10-Q · filed 2018-08-01 |
| 2017-12-31 | $1.64M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |